# Champions Oncology, Inc.: Form 10-Q for the period ended Jan 31, 2010

- Company: [Champions Oncology, Inc.](/companies/csbr.md) (CIK 771856)
- Form: 10-Q
- Filed: 2010-03-17
- Accepted by EDGAR: Mar 17, 2010, 16:02 ET
- Period: 2010-01-31
- Accession: 0000950123-10-025556
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/771856/000095012310025556/c97863e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/771856/000095012310025556/

## Management's discussion and analysis

As filed, 16,865 characters.

*The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the financial statements and related notes that appear elsewhere in this report.*

### Forward-Looking Statements

This Quarterly Report on Form 10-Q, including Item 2, *Management’s Discussion and Analysis of Financial Condition and Results of Operations*, contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2009, as updated in our subsequent reports filed with the SEC, including any updates found in Part II, Item 1A of this or other reports on Form 10-Q. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

### Overview

The Company is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. Our Preclinical Platform is a novel approach based upon the implantation of primary human tumor fragments in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts™) in a manner that preserves the biological characteristics of the original human tumor. We believe that Biomerk Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients. The Company is building its Biomerk Tumorgraft platform through the procurement, development and characterization of numerous Tumorgrafts within each of several cancer types. Tumorgrafts are procured through agreements with a number of institutions in the U.S. and overseas and developed and tested through agreement with a U.S. based preclinical facility.

We are leveraging our preclinical platform to evaluate oncology drug candidates and to develop a portfolio of novel or repositioned drug candidates through pre-clinical or early clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. We believe this strategy will enable us to leverage the competencies of these partners or licensees to maximize our return on investment in a time frame that is shorter than for traditional drug development. We believe that this model is unlike that of many new biotechnology companies that look to bring the process of drug development through all phases of discovery, development, regulatory approvals, and marketing, which requires a very large financial commitment and a long development period, typically more than a decade, to commercialize. Thus far we have acquired or licensed three oncology drug candidates, SG410, TAR-1, and Bithionol. We have begun preclinical development of the lead candidate, SG410, through the use of contract facilities and have secured a preclinical supply of SG410 drug substance and developed a soluble form of the compound and we intend to evaluate its efficacy in Biomerk Tumorgrafts for several cancer types. If results are promising, it is our intention to continue preclinical development and then sell, partner or license SG410 for its remaining clinical development. The Company also entered into license agreements to develop and commercialize TAR-1 and Bithionol in October, 2009 and November, 2009, respectively.

We also offer our Biomerk Tumorgraft predictive preclinical platform and tumor specific data to physicians to provide information that may enhance personalized patient care options and to companies for evaluation of oncology drugs in a platform that integrates predictive testing with biomarker discovery. We provide Personalized Oncology services to physicians in the field of oncology by establishing and administering expert medical information panels for their patients to (i) arrange for testing, analysis and study of cancer tissues, as appropriate, (ii) analyze medical records and test results, and (iii) assist in understanding conventional and research options. The Company also develops and performs testing on Personalized Tumorgrafts™ to provide patients’ physicians personalized data on treatment drug options.

### Results of Operations

### Three Months Ended January 31, 2010 and 2009

#### Revenues

Revenues for the three months ended January 31, 2010 and 2009 were $742,000 and $984,000, respectively, a decrease of $242,000 or 25%.

Revenues from Personalized Oncology Services (“POS”) for the three months ended January 31, 2010 and 2009 were $325,000 and $901,000, respectively, a decrease of $576,000 or 64%. This decrease consisted of a $317,000 decrease in revenues from physician panels and a $259,000 decrease in tumorgraft implantations, tumorgraft studies, and vaccine studies. Payments for POS are generally received in advance and recorded as deferred revenue.

Revenues from Preclinical eValuation services for the three months ended January 31, 2010 and 2009 were $417,000 and $83,000, respectively, an increase of $334,000 or 402%. This increase is due to growth in both the number of studies being completed and customers entering into contracts for the Company’s preclinical eValuation services. The Company utilizes a proportional performance revenue recognition model for its preclinical eValuation services under which we recognize revenue as performance occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement, typically the delivery of reports to our customers documenting the results of our testing protocols. Payments, or partial payments, for Preclinical eValuation services are generally received in advance and recorded as deferred revenue.

#### Operating Expenses

Cost of Personalized Oncology Services for the three months ended January 31, 2010 and 2009 were $162,000 and $464,000, respectively, a decrease of $302,000 or 65% reflecting the $576,000 decrease in POS revenues.

Cost of Preclinical eValuation services for the three months ended January 31, 2010 and 2009, were $202,000 and $206,000, respectively, a decrease of $4,000 or 2%. During the third quarter of 2009 the Company realized lower a lower gross margin on preclinical eValuation service revenues primarily due to a contractually negotiated reduction in payments with one of the Company’s customers.

Research and development (“R&D”) expenses for the three months ended January 31, 2010 and 2009, were $566,000 and $435,000, respectively, an increase of $131,000 or 30%. This increase is primarily due to the recognition of $130,000 in licensing fees and costs in connection with our Bithionol licensing agreement.

General and administrative expenses for the three months ended January 31, 2010 and 2009, were $596,000 and $463,000, respectively, an increase of $133,000 or 29%. This increase is primarily due to our development of corporate infrastructure to support our increased generating activities of the Company and includes increased payroll, bonuses, consulting, legal, accounting, marketing, and office rent expenses.

#### Interest Income

Interest income for the three months ended January 31, 2010 and 2009, was $0 and $21,000, respectively. The decrease in interest income resulted from the Company’s decrease in assets held in interest bearing investments.

#### Net Loss

The Company’s net loss for the three months ended January 31, 2010 and 2009, was $784,000 and $563,000, respectively. The $221,000 increase in our net loss for the three months ended January 31, 2009, reflects the $242,000 decrease in revenues and a net decline of $21,000 in interest income offset by the $42,000 decrease in operating expenses.

### Nine Months Ended January 31, 2010 and 2009

#### Revenues

Revenues for the nine months ended January 31, 2010 and 2009, were $2,993,000 and $2,701,000, respectively, an increase of $292,000 or 11%.

Revenues from POS for the nine months ended January 31, 2010 and 2009, were $1,813,000 and $2,381,000, respectively, a decrease of $568,000 or 24%. This decrease of $568,000 consisted of a $1,052,000 decrease in revenues from physician panels offset by a $484,000 increase in tumorgraft implantations, tumorgraft studies, and vaccine contracts. Payments for POS are generally received in advance and recorded as deferred revenue.

Revenues from Preclinical eValuation services for the nine months ended January 31, 2010 and 2009, were $1,180,000 and $320,000, respectively, an increase of $860,000 or 269%. This increase is due to growth in both the number of studies being completed and customers entering into contracts for the Company’s preclinical eValuation services. The Company utilizes a proportional performance revenue recognition model for its preclinical eValuation services under which we recognize revenue as performance occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement, typically the delivery of reports to our customers documenting the results of our testing protocols. Payments, or partial payments, for Preclinical eValuation services are generally received in advance and recorded as deferred revenue.

#### Operating Expenses

Cost of Personalized Oncology Services for the nine months ended January 31, 2010 and 2009, were $783,000 and $1,059,000, respectively, a decrease of $276,000 or 26% reflecting the $568,000 decrease in POS revenues.

Cost of Preclinical eValuation services for the nine months ended January 31, 2010 and 2009, were $586,000 and $329,000, respectively, an increase of $257,000 or 78% reflecting the increase in Preclinical eValuation revenues. During the third quarter of 2009 the Company realized lower a lower gross margin on preclinical eValuation service revenues primarily due to a contractually negotiated reduction in payments with one of the Company’s customers.

Research and development expenses for the nine months ended January 31, 2010 and 2009, were $1,707,000 and $1,072,000, respectively, an increase of $635,000 or 59%. This increase is due to the $175,000 charge for the final payment made with our common stock for the acquisition of the SG410 patent, the recognition of licensing fees, and costs in connection with our TAR-1 licensing agreement of $208,000, recognition of $130,000 in licensing fees and costs for our Bithionol license agreement, and a $212,000 increase in tumorgraft acquisition and testing costs, offset by the cancelation of an amounts payable of $90,000 to certain vendors for lack of performance.

General and administrative expenses for the nine months ended January 31, 2010 and 2009, were $2,293,000 and $1,163,000, respectively, an increase of $1,130,000 or 97%. This increase is primarily due to our continuing development of corporate infrastructure to support our increased revenue generating activities of the Company including increased payroll, bonuses, consulting, legal, accounting, marketing, and office rent expenses.

#### Interest Income

Interest income for the nine months ended January 31, 2009 and 2008 was $5,000 and $67,000, respectively. The decrease in interest income resulted from the Company’s decrease in assets held in interest bearing investments.

#### Net Loss

The Company’s net loss for the nine months ended January 31, 2010 and 2009, was $2,371,000 and $855,000, respectively. The $1,516,000 increase in our net loss for the nine months ended January 31, 2010 reflects the $1,746,000 increase in operating expenses and a net decline of $62,000 in interest income offset by the $292,000 increase in revenues.

### Liquidity and Capital Resources

As of January 31, 2010, our source of liquidity was cash of $1,479,000 compared to $1,728,000 (exclusive of a $1,017,000 certificate of deposit) at April 30, 2009. Our cash decreased by $249,000 during the nine months ended January 31, 2010 due primarily to our use of cash in operations of $3,108,000 offset by the conversion to cash of our $1,017,000 certificate of deposit upon the maturity of that instrument and the net receipt of $2,075,000 from the private placement of our common stock. Additionally, we purchased property and equipment for $40,000, treasury stock for $188,000, and received cash of $3,000 from the exercise of warrants to purchase our common stock.

The Company’s working capital, defined as current assets less current liabilities, as of January 31, 2010 and April 30, 2009, was $1,256,000 and $1,166,000, respectively.

### Commitments and Contractual Obligations

There have been no material changes in our contractual obligations and other commercial commitments other than in the ordinary course of business since the end of fiscal year 2009. Information regarding our contractual obligations and commercial commitments is provided in our Annual Report on Form 10-K for the year ended April 30, 2009.

### Ability to Continue As a Going Concern

The Company’s ability to continue as a going concern is dependent upon the success of raising additional capital sufficient to meet the operating needs of the Company for at least the 12 month period subsequent to issuance of this quarterly report. In June 2009, the Company’s Board of Directors authorized management to begin the process of raising additional capital. There can be no assurance that management will be successful in raising capital on terms acceptable to the Company, if at all. The Company’s ability to successfully raise additional capital will depend on the condition of the capital markets and the Company’s financial condition and prospects. Even if the Company is able to successfully raise additional capital, such capital could be in the form of debt and could be at high interest rates and/or require the Company to comply with restrictive covenants that limit financial and business activities. In addition, even if the Company is able to successfully raise equity capital, this could dilute the interest of existing shareholders and/or be issued with preferential liquidation, dividend or voting rights to those currently held by the Company’s common stockholders.

### Off Balance Sheet Arrangements

We have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risk, contingent liabilities, or any other obligation under a variable interest in an unconsolidated entity that provides financing and liquidity support or market risk or credit risk support to the Company.

## Controls and procedures

As filed, 1,749 characters.

#### Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). Our management, including our acting principal executive officer and chief financial officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of a date within ninety (90) days of the filing date of this Form 10-Q quarterly report. Following this review and evaluation, management collectively determined that our disclosure controls and procedures are not effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to management, including our principal executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

#### Changes in Internal Controls

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) and 15d -15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

The Company continues to take steps to strengthen our system of internal control and disclosure control procedures in regards to the four material weaknesses as further discussed in our Annual Report on form 10-K for the fiscal year ended April 30, 2009.

Filed Mar 17, 2010.
Source: SEC EDGAR, the filing index for accession 0000950123-10-025556. Last ingested by Listed: Nov 10, 2026, 03:33 ET. No prices; not investment advice.
